Systemic therapy for cutaneous melanoma

Clin Plast Surg. 2010 Jan;37(1):127-46. doi: 10.1016/j.cps.2009.07.008.


This article provides a review of the current medical management of patients with high-risk and metastatic cutaneous melanoma, including a review of the use of adjuvant interferon therapy and a discussion of adjuvant treatments under evaluation. The use of standard chemotherapeutic agents for metastatic disease is discussed, with an emphasis on developmental therapeutics using targeted agents. This discussion includes a review of the immune therapy for metastatic melanoma, including newer immunomodulatory agents and cellular therapeutics that are expected to significantly impact the care of these patients.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Cancer Vaccines / therapeutic use
  • Chemotherapy, Adjuvant
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
  • Humans
  • Immunotherapy, Adoptive
  • Interferons / therapeutic use
  • Melanoma / secondary
  • Melanoma / surgery
  • Melanoma / therapy*
  • Skin Neoplasms / surgery
  • Skin Neoplasms / therapy*


  • Antineoplastic Agents
  • Cancer Vaccines
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Interferons